155 related articles for article (PubMed ID: 32669717)
1. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
Lyon AR; Babalis D; Morley-Smith AC; Hedger M; Suarez Barrientos A; Foldes G; Couch LS; Chowdhury RA; Tzortzis KN; Peters NS; Rog-Zielinska EA; Yang HY; Welch S; Bowles CT; Rahman Haley S; Bell AR; Rice A; Sasikaran T; Johnson NA; Falaschetti E; Parameshwar J; Lewis C; Tsui S; Simon A; Pepper J; Rudy JJ; Zsebo KM; Macleod KT; Terracciano CM; Hajjar RJ; Banner N; Harding SE
Gene Ther; 2020 Dec; 27(12):579-590. PubMed ID: 32669717
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
[TBL] [Abstract][Full Text] [Related]
3. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
[TBL] [Abstract][Full Text] [Related]
4. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
[TBL] [Abstract][Full Text] [Related]
5. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for heart failure.
Greenberg B
J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
[TBL] [Abstract][Full Text] [Related]
7. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
Penny WF; Hammond HK
Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
[TBL] [Abstract][Full Text] [Related]
8. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
Hajjar RJ; Zsebo K; Deckelbaum L; Thompson C; Rudy J; Yaroshinsky A; Ly H; Kawase Y; Wagner K; Borow K; Jaski B; London B; Greenberg B; Pauly DF; Patten R; Starling R; Mancini D; Jessup M
J Card Fail; 2008 Jun; 14(5):355-67. PubMed ID: 18514926
[TBL] [Abstract][Full Text] [Related]
9. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.
Jaski BE; Jessup ML; Mancini DM; Cappola TP; Pauly DF; Greenberg B; Borow K; Dittrich H; Zsebo KM; Hajjar RJ;
J Card Fail; 2009 Apr; 15(3):171-81. PubMed ID: 19327618
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.
Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Pogoda JM; Provost R; Guerrero J; Hajjar RJ; Zsebo KM
Gene Ther; 2016 Mar; 23(3):313-9. PubMed ID: 26699914
[TBL] [Abstract][Full Text] [Related]
11. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
[TBL] [Abstract][Full Text] [Related]
12. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts.
Karakikes I; Hadri L; Rapti K; Ladage D; Ishikawa K; Tilemann L; Yi GH; Morel C; Gwathmey JK; Zsebo K; Weber T; Kawase Y; Hajjar RJ
Mol Ther; 2012 Mar; 20(3):565-71. PubMed ID: 22215018
[TBL] [Abstract][Full Text] [Related]
13. Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.
Aguero J; Ishikawa K; Hadri L; Santos-Gallego CG; Fish KM; Kohlbrenner E; Hammoudi N; Kho C; Lee A; Ibáñez B; García-Alvarez A; Zsebo K; Maron BA; Plataki M; Fuster V; Leopold JA; Hajjar RJ
J Am Coll Cardiol; 2016 May; 67(17):2032-46. PubMed ID: 27126531
[TBL] [Abstract][Full Text] [Related]
14. [Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].
Hui HP; Li XY; Liu XH; Sun S; Lu XC; Liu T; Yang W
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):357-62. PubMed ID: 16776934
[TBL] [Abstract][Full Text] [Related]
15. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
Zhai Y; Luo Y; Wu P; Li D
J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
[TBL] [Abstract][Full Text] [Related]
16. Effect of SERCA2a overexpression in the pericardium mediated by the AAV1 gene transfer on rapid atrial pacing in rabbits.
Kuken BN; Aikemu AN; Xiang SY; Wulasihan MH
Genet Mol Res; 2015 Oct; 14(4):13625-32. PubMed ID: 26535677
[TBL] [Abstract][Full Text] [Related]
17. Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart.
Chaudhary KW; Rossman EI; Piacentino V; Kenessey A; Weber C; Gaughan JP; Ojamaa K; Klein I; Bers DM; Houser SR; Margulies KB
J Am Coll Cardiol; 2004 Aug; 44(4):837-45. PubMed ID: 15312868
[TBL] [Abstract][Full Text] [Related]
18. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
Gwathmey JK; Yerevanian A; Hajjar RJ
Hum Gene Ther; 2013 Nov; 24(11):937-47. PubMed ID: 24164241
[TBL] [Abstract][Full Text] [Related]
19. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.
Lipskaia L; Chemaly ER; Hadri L; Lompre AM; Hajjar RJ
Expert Opin Biol Ther; 2010 Jan; 10(1):29-41. PubMed ID: 20078230
[TBL] [Abstract][Full Text] [Related]
20. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.
Hayward C; Banner NR; Morley-Smith A; Lyon AR; Harding SE
Hum Gene Ther; 2015 May; 26(5):293-304. PubMed ID: 25914929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
